NCT04562389: Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
- State
- Under way
- Phase
- Phase 3
- People
- 353 taking part
- Started
- 11 Mar 2021
- Primary completion
- 20 Feb 2026
- Arms
- Phase 1a: Cohort 1: Selinexor 40 mg + Ruxolitinib BID, Phase 1a: Cohort 2: Selinexor 60 mg + Ruxolitinib BID, Phase 1b: Selinexor and Ruxolitinib BID, Phase 3: Selinexor 60 mg + Ruxolitinib BID
- Results
- None posted
- 24 Sep 2020: Trial registered
- 11 Mar 2021: Trial started